Halyard Health Inc. (HYH)

46.52
0.71 1.55
NYSE : Health Technology
Prev Close 45.81
Open 44.81
Day Low/High 44.63 / 47.10
52 Wk Low/High 38.00 / 72.96
Volume 329.24K
Avg Volume 415.70K
Exchange NYSE
Shares Outstanding 47.02M
Market Cap 2.69B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: Major Opportunities for Studious Investors

Jim Cramer's 'Mad Money' Recap: Major Opportunities for Studious Investors

This is a market with opportunities for individuals who take the time to analyze companies, events and economic trends, Cramer said.

Weekly Roundup

It was another busy week for the portfolio as we initiated two new positions and four holdings reported earnings.

Jim Cramer, Analysts on How to Invest in Health Care at Any Age

Jim Cramer, Analysts on How to Invest in Health Care at Any Age

Perspectives from Wall Street looks at how investors at any age can find opportunities in the health care sector.

We Would Buy More Halyard

This company is a slow-burn growth story.

Weekly Roundup

A close look at two new AAP names, Twenty-First Century Fox and Honeywell.

Buying More Halyard Health on Mixed Results

Investors seem to be overreacting, but our initial thesis holds up.

Weekly Roundup

We made a number of moves in the portfolio this week amid a flurry of earnings results and economic data.

Weekly Roundup

It was a busy earnings week for the portfolio, with seven holdings reporting strong first-quarter results.

Earnings and Marriage Season

Biotech companies are saying, "I do."

Weekly Roundup

We made a variety of moves in the portfolio this week, including initiating a new position.

Weekly Roundup

We initiated a new position this week and departed another, as the market rebounded from last week's sharp decline.

At Least Dollar and Oil Are Cooperating

The news isn't as good for the transports.

Weekly Roundup

We initiated two positions this past week.

Weekly Roundup

We initiated two new positions in the portfolio this week and exited two others, as the market couldn't keep last week's momentum.

Weekly Roundup

In options trading, boasts about rates of return can be very deceiving.

Weekly Roundup

We took some profits in two portfolio names this week as the Fed provided a catalyst for a market upsurge.

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

It's creating investment opportunities that just shouldn't exist, Cramer says.

Weekly Roundup

It was a busy week for the portfolio as we added to several holdings, initiated a new position and exited several names.

Bulking Up 2 Newest Positions

We'll add to Thermo Fisher and Halyard Health.

Weekly Roundup

We added to a pair of portfolio positions this week on weakness, as earnings reports remained strong and odds increased of an earlier Fed rate hike.

Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More

Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More

Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.

Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield

Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield

Investors have to pay attention to see what's really worth buying.

Halyard Q4 Results Top Consensus

We view the report as encouraging and reiterate our $60 price target.

Weekly Roundup

How does options activity compare with the last time we saw Nasdaq 5,000?

Selling Halyard Puts Is Attractive

Consider the tendency of options premiums to fall after an IPO, combined with the bullish view.

Weekly Roundup

This week, we initiated a position in a healthcare name and exited a high tech portfolio holding, as the market moved slightly higher.

Initiating a Position and Trimming Another

This new holding is No. 1 or 2 in nearly all of its markets.

Jim Cramer on the Stock Market: Spinoffs Are in Vogue

Jim Cramer on the Stock Market: Spinoffs Are in Vogue

The logic of owning the pure play is attractive.

Cramer: Spinoffs Are in Vogue

The logic of owning the pure play is attractive.

Cramer: I Would Buy Kimberly-Clark Today

The company came under fire but its outlook is great.